Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Greenlights GSK's Chronic HBV Antisense Oligo With Roche CDx Test

21 October 2026 · By · Wire by Fusion42

Published

21 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 21 October 2026 · Fusion42 review

The US FDA approved GSK's antisense oligonucleotide drug Hibsago (bepirovirsen) for treating certain chronic hepatitis B virus (HBV) patients, accompanied by a Roche companion diagnostic test.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 21 Oct 2026 and 22 Oct 2026.

◆ ◆ The Wire takeaway

Your biotech project now competes in the chronic hepatitis B space where a new FDA-approved antisense drug sets a care standard linked with Roche's test. You must adjust development and go-to-market plans to address a paired drug-diagnostic model.

◆ Coverage

3 sources · first reported 21 Oct 2026 · latest 22 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalchronic-hbvantisense-oligonucleotidecompanion-diagnosticgskroche